GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » ROIC %

Onconetix (Onconetix) ROIC % : -16.13% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Onconetix ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Onconetix's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was -16.13%.

As of today (2024-06-04), Onconetix's WACC % is 8.97%. Onconetix's ROIC % is -39.33% (calculated using TTM income statement data). Onconetix earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Onconetix ROIC % Historical Data

The historical data trend for Onconetix's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onconetix ROIC % Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
-4,000.00 -711.40 -1,005.00 -1,867.17 -38.34

Onconetix Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,455.85 -90.98 -60.87 -47.67 -16.13

Competitive Comparison of Onconetix's ROIC %

For the Biotechnology subindustry, Onconetix's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Onconetix's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's ROIC % distribution charts can be found below:

* The bar in red indicates where Onconetix's ROIC % falls into.



Onconetix ROIC % Calculation

Onconetix's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-17.847 * ( 1 - 0.03% )/( (1.198 + 91.863)/ 2 )
=-17.8416459/46.5305
=-38.34 %

where

Onconetix's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-14.384 * ( 1 - 1.09% )/( (91.863 + 84.552)/ 2 )
=-14.2272144/88.2075
=-16.13 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Onconetix  (NAS:ONCO) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Onconetix's WACC % is 8.97%. Onconetix's ROIC % is -39.33% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Onconetix ROIC % Related Terms

Thank you for viewing the detailed overview of Onconetix's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Onconetix (Onconetix) Business Description

Traded in Other Exchanges
Address
201 East Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has a product named Entadfi an FDA approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Executives
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Timothy R. Ramdeen director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Vuk Jeremic director BLUE WATER VACCINES INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
Cincinnati Cornerstone Investors Bwv I, Llc 10 percent owner 2900 READING ROAD, SUITE 410, CINCINNATI OH 45206
Cincinnati Cornerstone Capital Llc other: Manager-Cinti Cornerstone Inv. 2900 READING RD, SUITE 410, CINCINNATI OH 45206
Joseph Hernandez 10 percent owner, officer: CEO C/O MICROLIN BIO, INC., NEW YORK NY 10022
Simon Tarsh director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Erin Henderson officer: Chief Business Officer 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jon Garfield officer: CFO 11111 SANTA MONICA BLVD., SUITE 650, LOS ANGELES CA 90025
Michael Venerable director 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202

Onconetix (Onconetix) Headlines

From GuruFocus

Blue Water Biotech Issues Letter to Shareholders

By Marketwired 10-30-2023